N-羟基环丁烷羧酰胺 | 99623-08-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-羟基环丁烷羧酰胺
• 英文名称: (Z)-N'-hydroxycyclobutanecarboximidamide
• 英文别名: N'-hydroxycyclobutanecarboximidamide
• CAS: 99623-08-2
• 化学式: C₅H₁₀N₂O
• 分子量: 114.147
• InChiKey: DEAGOJXAHZYVRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2925290090

反应信息

• 作为反应物：
  描述：

  槟榔碱 、 N-羟基环丁烷羧酰胺 生成 3-cyclobutyl-5-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,4-oxadiazole
  参考文献：
  名称：

  SAUERBERG, PER;KINDTLER, JENS W.;NIELSEN, LONE;SHEARDOWN, MALCOLM J.;HONO+, J. MED. CHEM., 34,(1991) N, C. 687-692

  摘要：

  DOI：

文献信息

• [EN] NOVEL HETEROCYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021148420A1

  公开（公告）日：2021-07-29

  The invention provides novel heterocyclic compounds having thegeneral formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R4, m, n, and p are as described herein. Formula (I). Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

  这项发明提供了具有通式（I）的新型杂环化合物及其药学上可接受的盐，其中R1至R4、m、n和p如本文所述。通式（I）。还提供了包括这些化合物的药物组合物、制造这些化合物的方法以及将这些化合物用作药物的方法，特别是将这些化合物用作抗生素治疗或预防细菌感染及由此导致的疾病的方法。
• [EN] BENZAMIDE CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES BENZAMIDES DES RÉCEPTEUR CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2015161011A1

  公开（公告）日：2015-10-22

  The present invention is directed to benzamide compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及苯甲酰胺化合物，其为CGRP受体拮抗剂，用于治疗或预防涉及CGRP的疾病，如偏头痛。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及CGRP的疾病中的用途。
• [EN] HETEROCYCLIC GPCR AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS COUPLÉS AUX PROTÉINES G (GPCR) HÉTÉROCYCLIQUES
  申请人：PROSIDION LTD

  公开号：WO2010004348A1

  公开（公告）日：2010-01-14

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.

  式（I）的化合物或其药用可接受的盐是GPCR（GPR119）激动剂，可用于治疗糖尿病和肥胖。
• HETEROARYL-SUBSTITUTED PIPERIDINES
  申请人：Heimbach Dirk

  公开号：US20090306139A1

  公开（公告）日：2009-12-10

  The invention relates to novel heteroaryl-substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular diseases and tumour diseases.

  本发明涉及新型杂环芳基取代哌啶，其制备过程，其用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是心血管疾病和肿瘤疾病。
• Heteroaryl-substituted piperidines
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US08119663B2

  公开（公告）日：2012-02-21

  The invention relates to novel heteroaryl-substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular diseases and tumor diseases.

  本发明涉及新型杂环芳基取代哌啶，其制备过程，以及它们用于治疗和/或预防疾病的用途，以及用于制备治疗和/或预防疾病的药物，特别是心血管疾病和肿瘤疾病。